COCP
Cocrystal Pharma, Inc.
1.79
USD
This page is just a preview of the data found in TrendSpider’s full version
Cocrystal Pharma, Inc. stock is down -5.79% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 23.08% of the previous 15 December’s closed higher than November. 100% of analysts rate it a buy.
Cocrystal Pharma, Inc. focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection.
